187 related articles for article (PubMed ID: 37873509)
1. Efficacy, safety, and Pharmacoeconomics of Three Common Strategies for Pediatric Alopecia Areata Patients: A Retrospective Cohort Study.
Zhou J; Yang Y; Xu M; Lyu Z; Wu X
Clin Cosmet Investig Dermatol; 2023; 16():2947-2956. PubMed ID: 37873509
[TBL] [Abstract][Full Text] [Related]
2. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study.
Zhang W; Li X; Chen B; Zhang J; Torres-Culala KMT; Zhou C
Front Med (Lausanne); 2022; 9():891434. PubMed ID: 35801202
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
4. Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study.
Huang J; Deng S; Li J; Tang Y; Liu F; Liu Y; Rao S; Shi W
Acta Derm Venereol; 2023 Nov; 103():adv13475. PubMed ID: 37955531
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Husein-ElAhmed H; Abdulla N; Al-Obaidli A; Ali-Alam M; Steinhoff M
Dermatol Ther; 2022 Dec; 35(12):e15871. PubMed ID: 36177791
[TBL] [Abstract][Full Text] [Related]
6. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
Kibbie J; Kines K; Norris D; Dunnick CA
Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients.
Cranwell W; Meah N; Wall D; Bevin B; Laita B; Sinclair RD
Australas J Dermatol; 2024 Jun; ():. PubMed ID: 38831704
[TBL] [Abstract][Full Text] [Related]
8. Combined microneedling with topical vitamin D3 or bimatoprost versus microneedling alone in the treatment of alopecia areata: A comparative randomized trial.
Ali MS; Hafiz HSA; Ahmed NA; Galal SA
J Cosmet Dermatol; 2023 Apr; 22(4):1286-1296. PubMed ID: 36762396
[TBL] [Abstract][Full Text] [Related]
9. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
10. A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis.
Sharath S; Sardana K; Khurana A
Indian Dermatol Online J; 2024; 15(1):49-54. PubMed ID: 38282998
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis.
Behrangi E; Barough MS; Khoramdad M; Hejazi P; Koltapeh MP; Goodarzi A
J Cosmet Dermatol; 2022 Dec; 21(12):6644-6652. PubMed ID: 36177815
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of adipocyte-derived stem cells conditioned media combined with micro-injury in refractory patch of alopecia areata.
Lee SB; Shin HT; Byun JW; Shin J; Choi GS
Arch Dermatol Res; 2022 Aug; 314(6):527-532. PubMed ID: 34131795
[TBL] [Abstract][Full Text] [Related]
14. Experience with oral tofacitinib in severe alopecia areata with different clinical responses.
Dincer Rota D; Emeksiz MAC; Erdogan FG; Yildirim D
J Cosmet Dermatol; 2021 Sep; 20(9):3026-3033. PubMed ID: 33533091
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review.
Huang J; Li T; Tan Z; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Sep; 103():adv13418. PubMed ID: 37731213
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
Huang J; Qian P; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Dec; 103():adv12425. PubMed ID: 38112208
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
18. Systematic review - alopecia areata and tofacitinib in paediatric patients.
Bandeira A; Albino-Teixeira A; Magina S
Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
[TBL] [Abstract][Full Text] [Related]
19. Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics.
Lai VWY; Bokhari L; Sinclair R
Int J Dermatol; 2021 Sep; 60(9):1135-1139. PubMed ID: 34008179
[TBL] [Abstract][Full Text] [Related]
20. Superficial cryotherapy using dimethyl ether and propane mixture versus microneedling in the treatment of alopecia areata: A prospective single-blinded randomized clinical trial.
Aboeldahab S; Nada EEA; Assaf HA; Gouda ZA; Abu El-Hamd M
Dermatol Ther; 2021 Sep; 34(5):e15044. PubMed ID: 34176196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
